← All trials
NCT05725291
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 28, 2023
- Primary completion
- Jan 30, 2025
- Completion date
- Jul 30, 2025
- First posted
- Feb 13, 2023
- Last posted
- Jul 27, 2023
- Enrollment
- 48
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Multitude Therapeutics Inc.Lead sponsor
- Icon Cancer CenterOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.